NLS Pharmaceutics (NLSP) has released an update.
NLS Pharmaceutics Ltd. successfully held an extraordinary shareholders’ meeting in October 2024, where all proposed agenda items were approved by the attending quorum. The outcomes of the meeting are set to influence the company’s future, as detailed in the Form 6-K report filed with the SEC, which also integrates into the company’s existing Registration Statements on Form F-3.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
